Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
株式のランク #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
株価
$0.00244926
時価総額
$51.67K
変化(1日)
5.88%
変化(1年)
110.15%
GB
取引 Nuformix plc (NFX)

カテゴリー

Nuformix plc(NFX)の利益
Sep 2025 時点の利益 TTM: $-5.28M
Nuformix plc の最新の財務報告によると、同社の現在の利益は $-5.28M です。2024 年には $-4.88M の利益を上げ、これは 2023 年の利益 $-754.56K と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Nuformix plc の利益の推移(2014 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-5.28M 494.63%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
同業他社の利益
企業 利益 利益の差
$20.46B -387,521.89%
DK
$4.64B -88,033.93%
US
$5.23B -99,160.13%
US
$2.14B -40,584.12%
BE
$1.61B -30,671.66%
AU